BioSpace News Archive

Silence Therapeutics plc today announced the acceptance of a late-breaking clinical abstract on the ongoing SLN360.

Evaxion Biotech A/S announced today the publication of a paper on personalized therapy with EVX-01 in patients with metastatic melanoma in the open access, peer-reviewed journal OncoImmunology.

BiondVax Pharmaceuticals Ltd. announced that it is presenting at the Edison Open House: Global Healthcare 2022 conference.

Edesa Biotech, Inc. announced that Dr. Par Nijhawan, Chief Executive Officer, is scheduled to participate in a virtual event at the 2022 OBIO Investment Summit hosted by the Ontario Bioscience Innovation Organization.

Hepion Pharmaceuticals, Inc. today announced the results of a nonclinical research study showing that its clinical phase drug candidate, rencofilstat (CRV431), synergistically decreased liver tumor growth and extended mouse survival when combined with an anti-PD1 antibody, an immune checkpoint inhibitor (“ICI”).

Vaccinex, Inc. today reported positive interim response data in the Phase Ib segment of the KEYNOTE-B84 study of Vaccinex’s pepinemab in combination with Merck’s anti-PD-1 therapy Keytruda.

Adlai Nortye Ltd. announced that it has entered into a Global License Agreement with Xiamen Biotime Biotechnology Co., Ltd. (“Biotime”) for several compounds.

BioEclipse Therapeutics announced today the appointment of Mahmoud Mahmoudian, Ph.D., FRSC, to the BioEclipse Board of Directors.

Cortexyme Announces Clinical Hold on Atuzaginstat’s Investigational New Drug Application.

Veru Inc. today announced that it will report financial results for its fiscal 2022 first quarter, on Wednesday, February 9, 2022, before the market opens.